Vertex Pharmaceuticals, Inc.’s recently made public that its EVP, Chief Technical Ops. Off. Atkinson Edward Morrow III unloaded Company’s shares for reported $3.48 million on Jun 12 ’24. In the deal valued at $478.00 per share,7,288 shares were sold. As a result of this transaction, Atkinson Edward Morrow III now holds 15,972 shares worth roughly $7.68 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Bozic Carmen sold 2,280 shares, generating $1,089,840 in total proceeds. Upon selling the shares at $478.00, the EVP and CMO now owns 32,379 shares.
Before that, WAGNER CHARLES F JR sold 3,250 shares. Vertex Pharmaceuticals, Inc. shares valued at $1,495,000 were divested by the EVP & Chief Financial Officer at a price of $460.00 per share. As a result of the transaction, WAGNER CHARLES F JR now holds 47,137 shares, worth roughly $22.66 million.
Evercore ISI upgraded its Vertex Pharmaceuticals, Inc. [VRTX] rating to an Outperform from a an In-line in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid February with a ‘”an Outperform”‘ rating. Evercore ISI also remained covering VRTX and has decreased its forecast on February 06, 2024 with a “an In-line” recommendation from previously “an Outperform” rating. Bernstein revised its rating on February 02, 2024. It rated VRTX as “a Mkt perform” which previously was an “an Outperform”.
Price Performance Review of VRTX
On Friday, Vertex Pharmaceuticals, Inc. [NASDAQ:VRTX] saw its stock jump 0.35% to $480.73. Over the last five days, the stock has lost -0.48%. Vertex Pharmaceuticals, Inc. shares have risen nearly 18.15% since the year began. Nevertheless, the stocks have risen 40.99% over the past one year. While a 52-week high of $486.42 was reached on 06/07/24, a 52-week low of $335.82 was recorded on 04/18/24. SMA at 50 days reached $429.14, while 200 days put it at $399.24. A total of 0.64 million shares were traded, compared to the trading of 0.81 million shares in the previous session.
Levels Of Support And Resistance For VRTX Stock
The 24-hour chart illustrates a support level at 477.80, which if violated will result in even more drops to 474.86. On the upside, there is a resistance level at 483.60. A further resistance level may holdings at 486.46. The Relative Strength Index (RSI) on the 14-day chart is 70.74, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 8.27, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 11.20%. Stochastics %K at 84.45% indicates the stock is a selling.
